Wave's stock swells as it eyes approval following Phase II DMD victory

By Yahoo! Finance | Sep 25, 2024 at 06:48 AM EST

Wave Life Sciences is seeking accelerated approval for its Duchenne muscular dystrophy drug, leading to a surge in stock price. Positive Phase II trial data showed significant benefits and safety of WVE-N531, prompting plans for an FDA meeting.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.